1. Home
  2. ZKH vs PRME Comparison

ZKH vs PRME Comparison

Compare ZKH & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZKH Group Limited

ZKH

ZKH Group Limited

HOLD

Current Price

$2.94

Market Cap

469.9M

Sector

N/A

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$2.93

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
PRME
Founded
1998
2019
Country
China
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.9M
536.4M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
ZKH
PRME
Price
$2.94
$2.93
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.56
AVG Volume (30 Days)
71.6K
3.8M
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
$9.02
$7.06
Revenue Next Year
$10.41
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
55.28
52 Week Low
$1.92
$2.67
52 Week High
$3.90
$6.94

Technical Indicators

Market Signals
Indicator
ZKH
PRME
Relative Strength Index (RSI) 58.06 40.20
Support Level $2.88 $2.68
Resistance Level $2.97 $3.60
Average True Range (ATR) 0.14 0.17
MACD 0.01 -0.05
Stochastic Oscillator 84.31 15.00

Price Performance

Historical Comparison
ZKH
PRME

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. Majority of the revenues are derived from the PRC.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: